


PRODUCT: SB239063

ALTERNATE NAMES: SB-239063; SB239063; trans-4-[4-(4-fluorophenyl)-5-(2-methoxy-4-pyrimidinyl)-1H-imidazol-1-yl]-cyclohexanol; 4-(4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)-1H-imidazol-1-yl)cyclohexanol; 4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol

CATALOG#: B1699-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₀H₂₁FN₄O₂

MOLECULAR WEIGHT: 368.4

CAS NUMBER: 193551-21-2

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: SB239063 is a potent and selective p38 MAPK inhibitor with an IC₅₀ of 44 nM against p38 α MAPK while exhibited no activity against the γ - and δ -kinase isoforms.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

- Underwood D C et al. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung[J]. American Journal of Physiology-Lung Cellular and Molecular Physiology, 2000, 279(5): L895-L902.
- Strassburger M et al. Anti-inflammatory treatment with the p38 mitogen-activated protein kinase inhibitor SB239063 is neuroprotective, decreases the number of activated microglia and facilitates neurogenesis in oxygen-glucose-deprived hippocampal slice cultures[J]. European journal of pharmacology, 2008, 592(1): 55-61.

RELATED PRODUCTS:

- Doramapimod (Cat. No. 1954-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1, 5)

USAGE: *FOR RESEARCH USE ONLY! Not to be used in humans*